Trial Profile
ARTiST: Aromasin® Randomised TrIal +/- Sutent® as neoadjuvant Therapy for post-menopausal women with breast cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 Sep 2021
Price :
$35
*
At a glance
- Drugs Exemestane (Primary) ; Sunitinib (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Acronyms ARTiST
- 13 Oct 2017 Status changed from completed to discontinued.
- 04 Mar 2011 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
- 11 Mar 2009 New trial record